Compare Becton Dickinson and Co (BDX) vs Mercadolibre Inc (MELI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Mercadolibre Inc — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while Mercadolibre Inc trades at $1,924.05 (market cap $92.49B). The key difference: Mercadolibre Inc is the larger of the two by market cap, and Becton Dickinson and Co pays a 2.34% dividend while Mercadolibre Inc pays none. Which is the better fit depends on your goals.
| BDX | MELI | |
|---|---|---|
Market Cap | $48.93B | $92.49B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.39 | $2.51K |
52-Week Low | $138.62 | $1.55K |
Enterprise Value | $65.03B | $100.14B |
Dividend Yield | 2.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
MercadoLibre (MELI) trades at $1,820.69, down 0.51% in the last 24 hours, with a bearish technical signal. The stock shows strong revenue growth, with Q2 2026 EPS beating estimates at $9.19 versus $8.65 expected, but recent quarters have missed expectations. Valuation ratios like P/E of 49.53 are elevated, while profitability metrics include a 42.68% gross margin and 27.5% ROE. Analyst consensus is strongly bullish with a $2,020 price target, but technical indicators suggest near-term weakness.
Outlook remains positive long-term due to robust e-commerce and fintech expansion in Latin America, with revenue projected to hit $35.2B in 2026. Risks include margin pressures from heavy investments and competitive threats. The stock offers growth potential if profit trends improve, but investors face volatility from strategic spending and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
